GLUT-1 expression in ovarian carcinoma: Association with survival and response to chemotherapy

Guilherme Cantuaria, Anna Fagotti, Gabriella Ferrandina, Albino Magalhaes, Mehrdad Nadji, Roberto Angioli, Manuel Penalver, Salvatore Mancuso, Giovanni Scambia

Research output: Contribution to journalArticle

131 Citations (Scopus)

Abstract

BACKGROUND. Cancer cell growth is an energy-related process supported by an increased glucose metabolism. The objective of this study was to investigate the association of GLUT-1 with response to chemotherapy and outcome in patients with ovarian carcinoma. METHODS. Histologic sections of formalin fixed, paraffin embedded specimens from 113 primary ovarian carcinomas were stained for GLUT-1 by using polyclonal GLUT-1 antibody (Dako Co., Carpinteria, CA) and the labeled streptavidin biotin procedure. Intensity of GLUT-1 staining was compared with disease free survival (DFS), chemotherapy response, and other clinicopathologic characteristics. RESULTS. GLUT-1 cytoplasmic membrane staining was observed in 89 of 104 (85.6%) malignant tumors. Poorly differentiated tumors showed a trend to overexpress the GLUT-1 protein compared with the more differentiated counterparts (27.6% vs. 8.7%; P = 0.08). Patients who experienced a complete clinical response to chemotherapy were more frequently GLUT-1 positive than GLUT-1 negative (80% vs. 51.5%; P = 0.036). In multivariate analysis of advanced stage disease, residual tumor (P = 0.0001) and high GLUT-1 expression levels (P = 0.028) were the only independent variables that maintained a significant association with response to chemotherapy (P = 0.0001; chi-square = 38.13). In the subgroup of Stage III-IV (International Federation of Gynecology and Obstetrics patients showing a complete clinical response, GLUT-1 overexpression was associated with a shorter DFS. The median time to progression was 30 months in GLUT-1 strongly positive cases (> 50% of cancer cells positive) versus 60 months in GLUT-1 weakly positive cases (≤ 50% of cancer cells positive; P = 0.024). CONCLUSIONS. GLUT-1 status is an independent prognostic factor of response to chemotherapy in advanced stage ovarian carcinoma. Moreover, patients overexpressing GLUT-1 show a significantly shorter DFS. These results suggest that the assessment of GLUT-1 status may provide clinically useful prognostic information in patients with ovarian carcinoma.

Original languageEnglish
Pages (from-to)1144-1150
Number of pages7
JournalCancer
Volume92
Issue number5
DOIs
StatePublished - Sep 1 2001

Fingerprint

Carcinoma
Drug Therapy
Survival
Disease-Free Survival
Neoplasms
Glucose Transporter Type 1
Staining and Labeling
Streptavidin
Residual Neoplasm
Biotin
Gynecology
Paraffin
Formaldehyde
Obstetrics
Multivariate Analysis
Cell Membrane
Glucose
Antibodies
Growth

Keywords

  • Chemotherapy
  • GLUT-1
  • Ovarian carcinoma
  • Survival

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

GLUT-1 expression in ovarian carcinoma : Association with survival and response to chemotherapy. / Cantuaria, Guilherme; Fagotti, Anna; Ferrandina, Gabriella; Magalhaes, Albino; Nadji, Mehrdad; Angioli, Roberto; Penalver, Manuel; Mancuso, Salvatore; Scambia, Giovanni.

In: Cancer, Vol. 92, No. 5, 01.09.2001, p. 1144-1150.

Research output: Contribution to journalArticle

Cantuaria, G, Fagotti, A, Ferrandina, G, Magalhaes, A, Nadji, M, Angioli, R, Penalver, M, Mancuso, S & Scambia, G 2001, 'GLUT-1 expression in ovarian carcinoma: Association with survival and response to chemotherapy', Cancer, vol. 92, no. 5, pp. 1144-1150. https://doi.org/10.1002/1097-0142(20010901)92:5<1144::AID-CNCR1432>3.0.CO;2-T
Cantuaria, Guilherme ; Fagotti, Anna ; Ferrandina, Gabriella ; Magalhaes, Albino ; Nadji, Mehrdad ; Angioli, Roberto ; Penalver, Manuel ; Mancuso, Salvatore ; Scambia, Giovanni. / GLUT-1 expression in ovarian carcinoma : Association with survival and response to chemotherapy. In: Cancer. 2001 ; Vol. 92, No. 5. pp. 1144-1150.
@article{1b49c87d76824d229582be2a49c3f773,
title = "GLUT-1 expression in ovarian carcinoma: Association with survival and response to chemotherapy",
abstract = "BACKGROUND. Cancer cell growth is an energy-related process supported by an increased glucose metabolism. The objective of this study was to investigate the association of GLUT-1 with response to chemotherapy and outcome in patients with ovarian carcinoma. METHODS. Histologic sections of formalin fixed, paraffin embedded specimens from 113 primary ovarian carcinomas were stained for GLUT-1 by using polyclonal GLUT-1 antibody (Dako Co., Carpinteria, CA) and the labeled streptavidin biotin procedure. Intensity of GLUT-1 staining was compared with disease free survival (DFS), chemotherapy response, and other clinicopathologic characteristics. RESULTS. GLUT-1 cytoplasmic membrane staining was observed in 89 of 104 (85.6{\%}) malignant tumors. Poorly differentiated tumors showed a trend to overexpress the GLUT-1 protein compared with the more differentiated counterparts (27.6{\%} vs. 8.7{\%}; P = 0.08). Patients who experienced a complete clinical response to chemotherapy were more frequently GLUT-1 positive than GLUT-1 negative (80{\%} vs. 51.5{\%}; P = 0.036). In multivariate analysis of advanced stage disease, residual tumor (P = 0.0001) and high GLUT-1 expression levels (P = 0.028) were the only independent variables that maintained a significant association with response to chemotherapy (P = 0.0001; chi-square = 38.13). In the subgroup of Stage III-IV (International Federation of Gynecology and Obstetrics patients showing a complete clinical response, GLUT-1 overexpression was associated with a shorter DFS. The median time to progression was 30 months in GLUT-1 strongly positive cases (> 50{\%} of cancer cells positive) versus 60 months in GLUT-1 weakly positive cases (≤ 50{\%} of cancer cells positive; P = 0.024). CONCLUSIONS. GLUT-1 status is an independent prognostic factor of response to chemotherapy in advanced stage ovarian carcinoma. Moreover, patients overexpressing GLUT-1 show a significantly shorter DFS. These results suggest that the assessment of GLUT-1 status may provide clinically useful prognostic information in patients with ovarian carcinoma.",
keywords = "Chemotherapy, GLUT-1, Ovarian carcinoma, Survival",
author = "Guilherme Cantuaria and Anna Fagotti and Gabriella Ferrandina and Albino Magalhaes and Mehrdad Nadji and Roberto Angioli and Manuel Penalver and Salvatore Mancuso and Giovanni Scambia",
year = "2001",
month = "9",
day = "1",
doi = "10.1002/1097-0142(20010901)92:5<1144::AID-CNCR1432>3.0.CO;2-T",
language = "English",
volume = "92",
pages = "1144--1150",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "5",

}

TY - JOUR

T1 - GLUT-1 expression in ovarian carcinoma

T2 - Association with survival and response to chemotherapy

AU - Cantuaria, Guilherme

AU - Fagotti, Anna

AU - Ferrandina, Gabriella

AU - Magalhaes, Albino

AU - Nadji, Mehrdad

AU - Angioli, Roberto

AU - Penalver, Manuel

AU - Mancuso, Salvatore

AU - Scambia, Giovanni

PY - 2001/9/1

Y1 - 2001/9/1

N2 - BACKGROUND. Cancer cell growth is an energy-related process supported by an increased glucose metabolism. The objective of this study was to investigate the association of GLUT-1 with response to chemotherapy and outcome in patients with ovarian carcinoma. METHODS. Histologic sections of formalin fixed, paraffin embedded specimens from 113 primary ovarian carcinomas were stained for GLUT-1 by using polyclonal GLUT-1 antibody (Dako Co., Carpinteria, CA) and the labeled streptavidin biotin procedure. Intensity of GLUT-1 staining was compared with disease free survival (DFS), chemotherapy response, and other clinicopathologic characteristics. RESULTS. GLUT-1 cytoplasmic membrane staining was observed in 89 of 104 (85.6%) malignant tumors. Poorly differentiated tumors showed a trend to overexpress the GLUT-1 protein compared with the more differentiated counterparts (27.6% vs. 8.7%; P = 0.08). Patients who experienced a complete clinical response to chemotherapy were more frequently GLUT-1 positive than GLUT-1 negative (80% vs. 51.5%; P = 0.036). In multivariate analysis of advanced stage disease, residual tumor (P = 0.0001) and high GLUT-1 expression levels (P = 0.028) were the only independent variables that maintained a significant association with response to chemotherapy (P = 0.0001; chi-square = 38.13). In the subgroup of Stage III-IV (International Federation of Gynecology and Obstetrics patients showing a complete clinical response, GLUT-1 overexpression was associated with a shorter DFS. The median time to progression was 30 months in GLUT-1 strongly positive cases (> 50% of cancer cells positive) versus 60 months in GLUT-1 weakly positive cases (≤ 50% of cancer cells positive; P = 0.024). CONCLUSIONS. GLUT-1 status is an independent prognostic factor of response to chemotherapy in advanced stage ovarian carcinoma. Moreover, patients overexpressing GLUT-1 show a significantly shorter DFS. These results suggest that the assessment of GLUT-1 status may provide clinically useful prognostic information in patients with ovarian carcinoma.

AB - BACKGROUND. Cancer cell growth is an energy-related process supported by an increased glucose metabolism. The objective of this study was to investigate the association of GLUT-1 with response to chemotherapy and outcome in patients with ovarian carcinoma. METHODS. Histologic sections of formalin fixed, paraffin embedded specimens from 113 primary ovarian carcinomas were stained for GLUT-1 by using polyclonal GLUT-1 antibody (Dako Co., Carpinteria, CA) and the labeled streptavidin biotin procedure. Intensity of GLUT-1 staining was compared with disease free survival (DFS), chemotherapy response, and other clinicopathologic characteristics. RESULTS. GLUT-1 cytoplasmic membrane staining was observed in 89 of 104 (85.6%) malignant tumors. Poorly differentiated tumors showed a trend to overexpress the GLUT-1 protein compared with the more differentiated counterparts (27.6% vs. 8.7%; P = 0.08). Patients who experienced a complete clinical response to chemotherapy were more frequently GLUT-1 positive than GLUT-1 negative (80% vs. 51.5%; P = 0.036). In multivariate analysis of advanced stage disease, residual tumor (P = 0.0001) and high GLUT-1 expression levels (P = 0.028) were the only independent variables that maintained a significant association with response to chemotherapy (P = 0.0001; chi-square = 38.13). In the subgroup of Stage III-IV (International Federation of Gynecology and Obstetrics patients showing a complete clinical response, GLUT-1 overexpression was associated with a shorter DFS. The median time to progression was 30 months in GLUT-1 strongly positive cases (> 50% of cancer cells positive) versus 60 months in GLUT-1 weakly positive cases (≤ 50% of cancer cells positive; P = 0.024). CONCLUSIONS. GLUT-1 status is an independent prognostic factor of response to chemotherapy in advanced stage ovarian carcinoma. Moreover, patients overexpressing GLUT-1 show a significantly shorter DFS. These results suggest that the assessment of GLUT-1 status may provide clinically useful prognostic information in patients with ovarian carcinoma.

KW - Chemotherapy

KW - GLUT-1

KW - Ovarian carcinoma

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=0035446816&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035446816&partnerID=8YFLogxK

U2 - 10.1002/1097-0142(20010901)92:5<1144::AID-CNCR1432>3.0.CO;2-T

DO - 10.1002/1097-0142(20010901)92:5<1144::AID-CNCR1432>3.0.CO;2-T

M3 - Article

C2 - 11571727

AN - SCOPUS:0035446816

VL - 92

SP - 1144

EP - 1150

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 5

ER -